SCHEMBL1327342

SCHEMBL1327342

CCOC(=O)C1CCN(Cc2c(Oc3ccc(C(N)=O)c(O)c3)cc(-c3c(CC)cccc3CC)nc2C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.45
KDM4E B2RXH2 6/20 0.45
MAPT P10636 3/20 0.45
CCR8 P51685 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
POLB P06746 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 1/20 0.42
PARP10 Q53GL7 1/20 0.42
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
ALOX12 P18054 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1329153 0.92 CD274 (0.37) ALDH1A1KDM4EMAPTCCR8MAPK1
SCHEMBL2141460 0.91 LMNA (0.34) ALDH1A1MAPTMAPK1POLBTSHR
SCHEMBL1328878 0.88 SCN9A (0.41) KDM4E
SCHEMBL1327910 0.87 SCN9A (0.43) ALDH1A1KDM4EMAPK1HSD17B10TP53
SCHEMBL1327736 0.87 SCN9A (0.34) PARP10KMT2AMEN1
SCHEMBL1330011 0.86 CD274 (0.36) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL1328814 0.86 SCN9A (0.36) KDM4EPOLBL3MBTL1
SCHEMBL1330327 0.85 SOS1 (0.36) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL1327260 0.85 LMNA (0.34) MAPTTSHRPARP10NPSR1
SCHEMBL1329213 0.85 LMNA (0.34) MAPTTSHRPARP10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 ALDH1A1 1966/4885KDM4E 2088/4885MAPT 4726/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 ALDH1A1 1966/4885KDM4E 2088/4885MAPT 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.